Dasatinib, as a tyrosine kinase inhibitor, has contraindications mainly related to specific disease states, drug interactions, and special populations. Clinical use requires strict evaluation of the patient's basic condition to avoid serious adverse reactions.

1. Absolute contraindications

(1) Severe liver dysfunction: Child Pugh Class C patients are contraindicated as significant inhibition of drug metabolism may lead to toxic accumulation.

(2) Allergies to dasatinib or excipients: Use is prohibited for individuals with a history of severe hypersensitivity reactions (such as angioedema or Stevens Johnson syndrome).

2 Relative Contraindications

(1) Active bleeding: When platelet count is less than 50 × 10 ⁹/L or there is active gastrointestinal bleeding, medication should be suspended.

(2) Serious cardiovascular disease: Patients with QT interval prolongation>500ms and uncontrolled heart failure should carefully evaluate the risk benefit ratio.

3 Special Population Restrictions

(1) Pregnancy period: Animal experiments have shown embryotoxicity, human data is limited, and it is contraindicated during pregnancy (FDA pregnancy grade D).

(2) Breastfeeding period: Medications can be excreted through breast milk, and medication should be stopped or breastfeeding should be terminated during breastfeeding.

4 contraindications for drug interactions

(1) Strong CYP3A4 inducers, such as rifampicin and phenytoin sodium, can reduce the blood concentration of dasatinib and should be avoided in combination.

(2) Proton pump inhibitors: Omeprazole and other drugs significantly affect the absorption of dasatinib, and it is recommended to switch to H2 receptor antagonists.

Long term use potential of dasatinib

(1) Dasatinib can be used for a long time, but it needs to be strictly monitored by a doctor.

(2) The long-term use time depends on disease control and patient tolerance.

6 Precautions for long-term use

(1) Regularly conduct blood tests, liver function tests, and electrocardiogram monitoring.

(2) Pay close attention to possible side effects, such as thrombocytopenia, edema, etc.

(3) Avoid co administration with other drugs that may affect the QT interval.